Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/HDAC8_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/HDAC8_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HDAC8_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HDAC8_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HDAC8_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HDAC8_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0031647 | Colorectum | AD | regulation of protein stability | 108/3918 | 298/18723 | 6.33e-10 | 5.08e-08 | 108 |
GO:1903320 | Colorectum | AD | regulation of protein modification by small protein conjugation or removal | 86/3918 | 242/18723 | 9.43e-08 | 4.65e-06 | 86 |
GO:0051052 | Colorectum | AD | regulation of DNA metabolic process | 116/3918 | 359/18723 | 2.47e-07 | 1.00e-05 | 116 |
GO:0031396 | Colorectum | AD | regulation of protein ubiquitination | 72/3918 | 210/18723 | 4.50e-06 | 1.21e-04 | 72 |
GO:0031397 | Colorectum | AD | negative regulation of protein ubiquitination | 34/3918 | 83/18723 | 2.66e-05 | 5.04e-04 | 34 |
GO:1903321 | Colorectum | AD | negative regulation of protein modification by small protein conjugation or removal | 37/3918 | 95/18723 | 4.49e-05 | 7.83e-04 | 37 |
GO:0006325 | Colorectum | AD | chromatin organization | 119/3918 | 409/18723 | 4.85e-05 | 8.33e-04 | 119 |
GO:0032204 | Colorectum | AD | regulation of telomere maintenance | 31/3918 | 80/18723 | 2.01e-04 | 2.67e-03 | 31 |
GO:0033044 | Colorectum | AD | regulation of chromosome organization | 60/3918 | 187/18723 | 2.25e-04 | 2.94e-03 | 60 |
GO:0007063 | Colorectum | AD | regulation of sister chromatid cohesion | 12/3918 | 21/18723 | 3.02e-04 | 3.62e-03 | 12 |
GO:0000723 | Colorectum | AD | telomere maintenance | 43/3918 | 131/18723 | 9.77e-04 | 9.20e-03 | 43 |
GO:0007062 | Colorectum | AD | sister chromatid cohesion | 23/3918 | 62/18723 | 2.51e-03 | 1.92e-02 | 23 |
GO:00316471 | Colorectum | SER | regulation of protein stability | 86/2897 | 298/18723 | 2.56e-09 | 2.42e-07 | 86 |
GO:19033201 | Colorectum | SER | regulation of protein modification by small protein conjugation or removal | 70/2897 | 242/18723 | 6.84e-08 | 4.42e-06 | 70 |
GO:00313961 | Colorectum | SER | regulation of protein ubiquitination | 62/2897 | 210/18723 | 1.69e-07 | 9.71e-06 | 62 |
GO:00313971 | Colorectum | SER | negative regulation of protein ubiquitination | 29/2897 | 83/18723 | 9.72e-06 | 3.22e-04 | 29 |
GO:19033211 | Colorectum | SER | negative regulation of protein modification by small protein conjugation or removal | 30/2897 | 95/18723 | 6.29e-05 | 1.46e-03 | 30 |
GO:00510521 | Colorectum | SER | regulation of DNA metabolic process | 83/2897 | 359/18723 | 8.03e-05 | 1.77e-03 | 83 |
GO:00063251 | Colorectum | SER | chromatin organization | 89/2897 | 409/18723 | 4.15e-04 | 6.17e-03 | 89 |
GO:00322041 | Colorectum | SER | regulation of telomere maintenance | 24/2897 | 80/18723 | 7.57e-04 | 9.73e-03 | 24 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HDAC8 | SNV | Missense_Mutation | | c.1106T>A | p.Ile369Asn | p.I369N | Q9BY41 | protein_coding | deleterious(0) | benign(0.388) | TCGA-A2-A0YF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unspecific | Arimidex | SD |
HDAC8 | SNV | Missense_Mutation | | c.463N>G | p.Leu155Val | p.L155V | Q9BY41 | protein_coding | tolerated(1) | benign(0.003) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
HDAC8 | SNV | Missense_Mutation | rs397515417 | c.932N>T | p.Thr311Met | p.T311M | Q9BY41 | protein_coding | deleterious(0.03) | probably_damaging(0.996) | TCGA-A8-A09I-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
HDAC8 | insertion | In_Frame_Ins | novel | c.365_366insAAGATATATTGTTTCCCCTACCAAGTTTGAAAAAGATTCTTT | p.Ala122_Ala123insArgTyrIleValSerProThrLysPheGluLysAspSerPhe | p.A122_A123insRYIVSPTKFEKDSF | Q9BY41 | protein_coding | | | TCGA-A7-A0CD-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
HDAC8 | insertion | Nonsense_Mutation | novel | c.141_142insGGAGAATCGCTTGAACCCCGGAGGTGAAGG | p.Ala47_Tyr48insGlyGluSerLeuGluProArgArgTerArg | p.A47_Y48insGESLEPRR*R | Q9BY41 | protein_coding | | | TCGA-AO-A0JF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD |
HDAC8 | SNV | Missense_Mutation | novel | c.926N>T | p.Ala309Val | p.A309V | Q9BY41 | protein_coding | tolerated(0.19) | benign(0.076) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HDAC8 | SNV | Missense_Mutation | | c.567N>G | p.Phe189Leu | p.F189L | Q9BY41 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-BI-A0VR-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
HDAC8 | SNV | Missense_Mutation | novel | c.425A>G | p.His142Arg | p.H142R | Q9BY41 | protein_coding | deleterious(0.01) | probably_damaging(0.997) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
HDAC8 | SNV | Missense_Mutation | | c.170T>G | p.Val57Gly | p.V57G | Q9BY41 | protein_coding | deleterious(0) | possibly_damaging(0.623) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HDAC8 | SNV | Missense_Mutation | novel | c.616N>A | p.Gly206Arg | p.G206R | Q9BY41 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-ZJ-AAXU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PMID29671355-Compound-21 | | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | BELINOSTAT | BELINOSTAT | 25937017 |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 187051792 | PANOBINOSTAT | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | PMID29671355-Compound-36 | | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 187051797 | APICIDIN | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | ENTINOSTAT | ENTINOSTAT | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | BML-210 | CHEMBL324053 | 16921367 |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | BELINOSTAT | BELINOSTAT | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | inhibitor | 310264675 | CUDC-101 | |
55869 | HDAC8 | DRUGGABLE GENOME, ENZYME, TRANSCRIPTION FACTOR | | ROMIDEPSIN | ROMIDEPSIN | |